Friday 19 April

Dolutegravir, new HIV drug

HIV drugs: Dolutegravir, the new kid on the block Nomatter Ndebele, NSP Review journalist As the fight against HIV/AIDS continues, researchers and health clinicians are looking towards a future that will see low to middle income countries having access to better medication and more cost-effective drugs. While the current first-line Continue Reading